Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy

Journal of Hepatology

Volumn 53, Issue 2, 2010, Pages 261-266

  Tak, Won Young ^a   Park, Soo Young ^a   Cho, Chang Min ^a   Jung, Min Kyu ^a   Jeon, Seong Woo ^a   Kweon, Young Oh ^a   Park, Ji Young ^a   Sohn, Yoon Kyung ^a  

^a Kyungpook National University School of Medicine   (South Korea)

Author keywords

Clevudine; Hepatitis B; Mitochondrial myopathy

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLEVUDINE; CREATINE KINASE; ENTECAVIR; FRUCTOSE BISPHOSPHATE ALDOLASE; LACTATE DEHYDROGENASE; LACTIC ACID; LAMIVUDINE; MUSCLE ENZYME; MYOGLOBIN; ANTIVIRUS AGENT; LACTIC ACID DERIVATIVE; URACIL ARABINOSIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROMYOGRAPHY; EXERCISE; FEMALE; FOLLOW UP; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LACTATE BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; MALE; MEDICAL HISTORY; MITOCHONDRIAL TOXICITY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; MYOSITIS; NERVE CONDUCTION; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; EXERCISE TOLERANCE; HEPATITIS B, CHRONIC; METABOLISM; MIDDLE AGED; MUSCLE DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; SKELETAL MUSCLE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; ARABINOFURANOSYLURACIL; BIOPSY; CREATINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; L-LACTATE DEHYDROGENASE; LACTATES; MALE; MIDDLE AGED; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DISEASES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77955304449     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.03.006     Document Type: Article

References (30)

1. D. Lavanchy Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepat 11 2004 97 107
2. W.S. Ayoub, and E.B. Keeffe Review article: current antiviral therapy of chronic hepatitis B Aliment Pharmacol Ther 28 2008 167 177
3. T.A. Shamliyan, R. MacDonald, A. Shaukat, B.C. Taylor, J.M. Yuan, and J.R. Johnson Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference Ann Intern Med 150 2009 111 124
4. R. Chin, T. Shaw, J. Torresi, V. Sozzi, C. Trautwein, and T. Bock In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil Antimicrob Agents Chemother 45 2001 2495 2501
5. C.K. Chu, T. Ma, K. Shanmuganathan, C. Wang, Y. Xiang, and S.B. Pai Use of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus Antimicrob Agents Chemother 39 1995 979 981
6. G.Q. Yao, S.H. Liu, E. Chou, M. Kukhanova, C.K. Chu, and Y.C. Cheng Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil Biochem Pharmacol 51 1996 941 947
7. S. Balakrishna Pai, S.H. Liu, Y.L. Zhu, C.K. Chu, and Y.C. Cheng Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5- methyl-beta-L-arabinofuranosyl uracil Antimicrob Agents Chemother 40 1996 380 386
8. T. Ma, S.B. Pai, Y.L. Zhu, J.S. Lin, K. Shanmuganathan, and J. Du Structure-activity relationships of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl) pyrimidine nucleosides as anti-hepatitis B virus agents J Med Chem 39 1996 2835 2843
9. C.K. Chu, F.D. Boudinot, S.F. Peek, J.H. Hong, Y. Choi, and B.E. Korba Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent Antivir Ther 3 Suppl. 3 1998 113 121
10. B.C. Yoo, J.H. Kim, Y.H. Chung, K.S. Lee, S.W. Paik, and S.H. Ryu Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B Hepatology 45 2007 1172 1178
11. B.C. Yoo, J.H. Kim, T.H. Kim, K.C. Koh, S.H. Um, and Y.S. Kim Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression Hepatology 46 2007 1041 1048
12. W.Y. Tak, S.Y. Park, M.K. Jung, S.W. Jeon, C.M. Cho, and Y.O. Kweon Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients Hepatol Res 39 2009 944 947
13. J.I. Seok, D.K. Lee, C.H. Lee, M.S. Park, S.Y. Kim, and H.S. Kim Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA Hepatology 49 2009 2080 2086
14. B.K. Kim, J. Oh, S.Y. Kwon, W.H. Choe, S.Y. Ko, and K.H. Rhee Clevudine myopathy in patients with chronic hepatitis B J Hepatol 51 2009 829 834
15. European Association for Study of Liver Disease EASL Clinical Practice Guidelines: management of chronic hepatitis B J Hepatol 50 2009 227 242
16. A.S. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
17. K.P. Batts, and J. Ludwig Chronic hepatitis. An update on terminology and reporting Am J Surg Pathol 19 1995 1409 1417
18. K.A. Vincent, A.J. Carr, J. Walburn, D.L. Scott, and M.R. Rose Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL) Neurology 68 2007 1051 1057
19. J.M. Gregson, M.J. Leathley, A.P. Moore, T.L. Smith, A.K. Sharma, and C.L. Watkins Reliability of measurements of muscle tone and muscle power in stroke patients Age Ageing 29 2000 223 228
20. R. McKenzie, M.W. Fried, R. Sallie, H. Conjeevaram, A.M. Di Bisceglie, and Y. Park Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B N Engl J Med 333 1995 1099 1105
21. H.S. Lee, Y.H. Chung, K. Lee, K.S. Byun, S.W. Paik, and J.Y. Han A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B Hepatology 43 2006 982 988
22. T. Dagan, C. Sable, J. Bray, and M. Gerschenson Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: what is the evidence? Mitochondrion 1 2002 397 412
23. R. Hu, L. Li, B. Degreve, G.E. Dutschman, W. Lam, and Y.C. Cheng Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2′-deoxy-2′-fluoro-beta-L-arabinofuranosyl)-5- methyluracil (Clevudine) and 2′,3′-didehydro-2′,3′- dideoxythymidine in cells Antimicrob Agents Chemother 49 2005 2044 2049
24. P. Krishnan, Q. Fu, W. Lam, J.Y. Liou, G. Dutschman, and Y.C. Cheng Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase J Biol Chem 277 2002 5453 5459
25. S.H. Liu, K.L. Grove, and Y.C. Cheng Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-beta-L- arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase Antimicrob Agents Chemother 42 1998 833 839
26. O.S. Tehrani, K.A. Douglas, J.M. Lawhorn-Crews, and A.F. Shields Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2 Eur J Nucl Med Mol Imaging 35 2008 1480 1488
27. S.G. Lim, N. Leung, H.W. Hann, G.K. Lau, C. Trepo, and H. Mommeja-Marin Clinical trial: a phase II, randomized study evaluating the safety, pharmacokinetics and anti-viral activity of clevudine for 12 weeks in patients with chronic hepatitis B Aliment Pharmacol Ther 27 2008 1282 1292
28. P. Marcellin, H. Mommeja-Marin, S.L. Sacks, G.K. Lau, D. Sereni, and J.P. Bronowicki A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B Hepatology 40 2004 140 148
29. S.Y. Ko, S.Y. Kwon, W.H. Choe, B.K. Kim, K.H. Kim, and C.H. Lee Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study Antivir Ther 14 2009 585 590
30. X.S. Zhang, R. Jin, S.B. Zhang, and M.L. Tao Clinical features of adverse reactions associated with telbivudine World J Gastroenterol 14 2008 3549 3553